Phaseline

Companies › Pfizer

Pfizer: clinical trials, targets and expected readouts

89 active drug programs in 535 registered trials: 254 Phase 2, 131 Phase 1, 130 Phase 3, 20 Phase 4; Oncology, Other, Infectious disease, Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Rimegepant
Calcitonin gene-related peptide type 1 receptor antagonist
CALCRLPhase 4Acute Treatment of Migraine; Menstrual Migraine; Preventive Treatment of Migraine; Pediatric Migraine …Nov 2026
Encorafenib
Serine/threonine-protein kinase B-raf inhibitor
BRAFPhase 4Solid Tumors; Melanoma; Neoplasms; Metastatic Colorectal Cancer …Jan 2027
Elranatamab
T cell surface glycoprotein CD3 binding agent; Tumor necrosis factor receptor superfamily member 17 binding agent
CD3E, CD3G, CD3D, TNFRSF17Phase 4Multiple Myeloma; Multiple Myeloma, Newly Diagnosed; Relapsed Refractory Multiple Myeloma (RRMM); Refractory Multiple Myeloma …May 2027
crizotinib
Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor
MET, ALK, EML4, NPM1, ROS1Phase 4NSCLCMar 2028
Tisotumab Vedotin
Tubulin inhibitor; Coagulation factor III binding agent
Tubulin, F3Phase 4Cervical CancerDec 2028
Lorlatinib (PF-06463922)
ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor
ALK, EML4Phase 4Non-Small-Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Ganglioneuroblastoma; Non Small Cell Lung Cancer …Dec 2028
Binimetinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 4Solid Tumors; MelanomaJul 2029
tilrekimig (PF-07275315)
IL-13 receptor alpha-1 antagonist
IL13Phase 3Atopic Dermatitis; Asthma; Moderate to Severe Chronic Obstructive Pulmonary Disease; HealthyNov 2026
Ritlecitinib
Tyrosine-protein kinase JAK3 inhibitor; TEC family kinase inhibitor
JAK3, ITK, BMX, TEC, TXKPhase 3Severe Alopecia Areata; Vitiligo; Stable Nonsegmental Vitiligo; Alopecia Areata …Dec 2026
Sasanlimab
Programmed cell death protein 1 antagonist
PDCD1Phase 3Non-muscle Invasive Bladder Cancer; Urothelial Carcinoma Bladder; Metastatic Renal Cell Carcinoma; Advanced Clear Cell Renal Carcinoma (Ccrcc)Dec 2026
CMP 001
6-valent OspA-based Lyme disease vaccine
ESR1, OSPABPhase 3Lyme Disease; Advanced Malignancies; Lyme Borreliosis; Advanced Breast Cancer …Dec 2026
vepdegestrant
Estrogen receptor degrader (SERD)
ESR1Phase 3Breast Cancer; Healthy ParticipantsDec 2026
Palbociclib
CDK6/cyclin D1 inhibitor; Cyclin-dependent kinase 4/cyclin D1 inhibitor
CCND1, CDK6, CDK4Phase 3Breast Cancer; Ewing Sarcoma; Breast Cancer Recurrent; Metastatic Breast Cancer …Dec 2026
Avelumab
Programmed cell death 1 ligand 1 other
CD274Phase 3Advanced MalignanciesDec 2026
Lorlatanib
ALK inhibitor
ALKPhase 3Advanced MalignanciesDec 2026
PF04518600–Phase 3Advanced MalignanciesDec 2026
Talazoparib
Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor
PARP2, PARP1Phase 3Advanced Malignancies; mCRPC; Prostate Cancer; Urothelial Carcinoma …Dec 2026
Utomilumab
Tumor necrosis factor receptor superfamily member 9 agonist
TNFRSF9Phase 3Advanced Malignancies; Stage III Breast Cancer; Breast Cancer; Advanced Malignant Solid NeoplasmDec 2026
trastuzumab
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 3Colorectal Neoplasms; Uterine Neoplasms; Anatomic Stage IV Breast Cancer AJCC v8; Elderly Females …Dec 2026
tucatinib
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 3HER2 Positive Breast Cancer; Colorectal Neoplasms; HER2-positive Breast Cancer; Uterine Neoplasms …Dec 2026
Respiratory Syncytial Virus Pre-Fusion Glycoprotein F
Fusion glycoprotein F0 vaccine antigen
–Phase 3Lower Respiratory Tract Illness; Respiratory Syncytial Virus (RSV); Adult; RSV Infection …Jan 2027
Cetuximab
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 3Neoplasms; Metastatic Colorectal CancerJan 2027
Berobenatide (PF-08653944, MET097)
Dual GLP-1R/GIPR agonist
GIPR, GLP1RPhase 3Obesity and Overweight; Obesity; Apnea; Overweight …Jan 2027
PF-07220060
CDK4 inhibitor
CDK4Phase 3Breast Cancer; Advanced or Metastatic Breast Cancer; Locally Advanced or Metastatic ER+ HER2- Breast Cancer; LiposarcomaFeb 2027
Mevrometostat (PF-06821497)–Phase 3Metastatic Castrate Resistant Prostate Cancer (mCRPC); Metastatic Castration-Resistant Prostate Cancer; Metastatic Castration Sensitive Prostate Cancer (mCSPC); Metastatic Castration Resistant Prostate Cancer (mCRPC)Feb 2027
PG4
Multivalent pneumococcal conjugate vaccine
–Phase 3Pneumococcal DiseaseMar 2027
tofacitinib
Janus Kinase (JAK) inhibitor
JAK3, JAK1, JAK2, TYK2Phase 3Ulcerative ColitisMar 2027
Abrocitinib
Tyrosine-protein kinase JAK1 inhibitor
JAK1Phase 3Eczema; Atopic Dermatitis; Post-COVID Condition; Diabetes Mellitus, Type 1May 2027
marstacimab
Tissue factor pathway inhibitor inhibitor
TFPIPhase 3Hemophilia A; Severe Hemophilia AMay 2027
GBS6: Multivalent Group B streptococcus vaccine
6-valent Group B Streptococcus polysaccharide conjugate vaccine
–Phase 3Pneumococcal Disease; HealthyJun 2027
sigvotatug vedotin
Integrin beta-6 binding agent
ITGB6Phase 3Carcinoma, Non-Small-Cell Lung; Carcinoma, Non-Small Cell LungJun 2027
PF-07248144
KAT6 inhibitor
KAT6A, KAT6BPhase 3Breast Cancer; Locally Advanced or Metastatic ER+ HER2- Breast CancerJul 2027
Enzalutamide
Androgen Receptor antagonist
ARPhase 3Hormone Sensitive Prostate CancerJul 2027
Leuprolide
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 3Hormone Sensitive Prostate CancerJul 2027
Remdesivir
RNA-directed RNA polymerase L inhibitor; Replicase polyprotein 1ab inhibitor
3C, RDRPPhase 3COVID-19 Infection; SARS CoV-2 Post-Acute Sequelae; COVID-19; COVID - 19 …Sep 2027
ibuzatrelvir–Phase 3COVID-19 Infection; COVID-19 SARS-CoV-2 InfectionSep 2027
PF-08634404
Stimulator of Interferon genes (STING) agonist
TMEM173Phase 3Advanced Non-Small Cell Lung Cancer; Endometrial Neoplasms; Intestinal Neoplasms; Small Cell Lung Cancer …Oct 2027
Fidanacogene Elaparvovec (PF-06838435)
Coagulation factor IX exogenous gene
F9Phase 3Hemophilia B; Hemophilia AFeb 2028
PF-08046054
Anti-PD-L1 antibody-drug conjugate
PDCD1LG1Phase 3Non-small Cell CarcinomaMar 2028
Sigvotatug Vedotin
Integrin beta-6 binding agent
ITGB6Phase 3Non-Small Cell Lung Cancer; Advanced/Metastatic Non-Small Cell Lung CancerSep 2028
C. difficile vaccine formulation 1
Toxoid-based Clostridioides difficile vaccine
–Phase 3Clostridoides Difficile Associated DiseaseDec 2028
Etrasimod
Sphingosine 1-phosphate receptor Edg-1 agonist; Sphingosine 1-phosphate receptor Edg-6 modulator; Sphingosine 1-phosphate receptor Edg-1 modulator
S1PR1, S1PR4, S1PR5Phase 3Ulcerative Colitis; Colitis, Ulcerative; Healthy Participant; PouchitisJun 2029
Dazukibart
Interferon beta inhibitor
IFNB1Phase 3Myositis; DermatomyositisJul 2030
PF-06939926
Gene therapy for DMD
–Phase 3Duchenne Muscular DystrophyApr 2039
giroctocogene fitelparvovec
AAV5 gene therapy delivering factor VIII
F8Phase 3Hemophilia AFeb 2040
Nirmatrelvir (PF-07321332)
SARS coronavirus 3C-like proteinase inhibitor
3CLPhase 3COVID-19; COVID-19, Long Haul–
PF-07055480 / Giroctocogene Fitelparvovec
Recombinant AAV2/6 human Factor VIII gene therapy
F8Phase 3Hemophilia A–
PF-07264660–Phase 2Atopic DermatitisNov 2026
PF-07104091–Phase 2Small Cell Lung CancerDec 2026
PF-08653945–Phase 2OverweightJan 2027
Osivelotor–Phase 2Sickle Cell Disease; HealthyFeb 2027
PF-07328948–Phase 2Heart Failure; Hepatic Impairment; Renal ImpairmentFeb 2027
Aztreonam
Bacterial penicillin-binding protein inhibitor
–Phase 2Gram-negative Bacterial Infections; Advanced Non Small Cell Lung CancerMar 2027
tisotumab vedotin
Tubulin inhibitor; Coagulation factor III binding agent
Tubulin, F3Phase 2Colorectal NeoplasmsMar 2027
aztreonam-avibactam (ATM-AVI)
β-lactam antibiotic (aztreonam) combined with β-lactamase inhibitor (avibactam)
MMPBLA, CTXMPhase 2Gram-negative Bacterial InfectionApr 2027
Vaccine Candidate #1
mRNA vaccine targeting influenza virus
–Phase 2Healthy AdultsJun 2027
ponsegromab
GDF15 neutralizing monoclonal antibody
GDF15Phase 2CachexiaJan 2028
PF-08049820–Phase 2Atopic DermatitisFeb 2028
PF-07850327 / ARV-471 / vepdegestrant
PROTAC ER degrader
ESR1Phase 2Locally Advanced or Metastatic ER+ HER2- Breast CancerAug 2029
Inotuzumab ozogamicin
CD22 binding agent
CD22Phase 2ACUTE LYMPHOBLASTIC LEUKEMIA; B Acute Lymphoblastic Leukemia; B-Cell Acute Lymphoblastic Leukaemia; Leukemia, Acute Lymphoblastic …May 2033
PF-06835375
CXCR5 inhibitor
CXCR5Phase 2Primary Immune Thrombocytopenia–
PF-07868489–Phase 2Pulmonary Hypertension–
prifetrastat
STAT3 inhibitor
–Phase 1Healthy ParticipantDec 2026
PF-07985631
unclear mechanism for IgA nephropathy
–Phase 1HealthyDec 2026
PF-08103402–Phase 1Healthy Volunteer StudyMar 2027
PF-08642534
GLP-1 receptor agonist
–Phase 1ObesityApr 2027
PF-07832837–Phase 1Healthy ParticipantsJun 2027
SEA-CD70
anti-CD70 antibody-drug conjugate
CD70Phase 1Myelodysplastic SyndromeJul 2027
Zavegepant (PF-07930207)
Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 antagonist; Calcitonin gene-related peptide type 1 receptor antagonist
RAMP1, CALCRLPhase 1Acute Treatment of Migraine; MigraineAug 2027
Atirmociclib
CDK4/6 inhibitor
CDK4, CDK6Phase 1Hepatic ImpairmentAug 2027
PF-07799544
BRAF inhibitor
BRAFPhase 1MelanomaAug 2027
PF-07799933
BRAF inhibitor
BRAFPhase 1MelanomaAug 2027
PF-08065010–Phase 1HealthySep 2027
PG4 vaccine in Buffer 1 with high dose PA-002
Multivalent pneumococcal conjugate vaccine
–Phase 1Streptococcus PneumoniaeOct 2027
PG4 vaccine in Buffer 1 with low dose PA-001
Multivalent pneumococcal conjugate vaccine
–Phase 1Streptococcus PneumoniaeOct 2027
PF-08046054/SGN-PDL1V
anti-PD-L1 antibody-drug conjugate
CD274Phase 1Carcinoma, Non-Small-Cell LungJan 2028
Carfilzomib
26S proteasome inhibitor
PSMD1, PSMB2, PSMB1, PSMB5, PSMB8Phase 1Multiple Myeloma; Newly Diagnosed; Plasma Cell Myeloma; Newly Diagnosed Multiple Myeloma …Feb 2028
Maplirpacept
CD47-SIRP alpha-directed immune checkpoint inhibitor
CD47Phase 1Multiple MyelomaFeb 2028
E coli vaccine 1 Dose A
Candidate vaccine against Escherichia coli
–Phase 1Healthy ParticipantsMay 2028
PF-08046876
Antibody-drug conjugate (ADC)
–Phase 1Advanced/Metastatic Solid TumorsJul 2028
PF-08046033–Phase 1Non-Small-Cell LungJul 2028
PF-08046054/SGN-PDL1V
PD-L1-targeted antibody-drug conjugate
PDCD1LG2Phase 1Advanced/Metastatic Non-Small Cell Lung CancerMar 2029
PF-08032562–Phase 1Advanced Breast CancerApr 2029
PF-07994525–Phase 1Advanced MalignanciesJul 2029
PF-08046050
CEACAM5-targeting antibody-drug conjugate
CEACAM5Phase 1Colorectal NeoplasmsSep 2029
PF-08052667
Anti-B6N antibody-drug conjugate
B6NPhase 1Non-muscle Invasive Bladder CancerJan 2030
PF-08098488–Phase 1Pancreatic Ductal AdenocarcinomaJan 2031
PF-07934040
panKRAS inhibitor
KRASPhase 1Carcinoma, Pancreatic Ductal–
PF-07999415–Phase 1Healthy–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT00999804trastuzumabPhase 2Breast CancerOncologyNov 2014
NCT03498378PalbociclibPhase 1Head and Neck Squamous Cell CarcinomaOncologyFeb 2020
NCT03314636CarfilzomibPhase 2MyelomaOncologyNov 2021
NCT04649359ElranatamabPhase 2Multiple MyelomaOncologyJun 2022
NCT04678362TalazoparibPhase 2Urothelial CarcinomaOncologyJul 2023
NCT05953350PalbociclibPhase 1Inhibition of Autophagy Synergizes Anti-tumor EffectOncologyMay 2024
NCT04370054PF-07055480 / Giroctocogene FitelparvovecPhase 3Hemophilia AHematologyJun 2024
NCT03911973TalazoparibPhase 1TNBC - Triple-Negative Breast CancerOncologyJul 2024
NCT04127110Lorlatinib (PF-06463922)Phase 2Non Small Cell Lung CancerOncologyJul 2024
NCT03709680PalbociclibPhase 2Ewing SarcomaOncologyAug 2024
NCT05041842tucatinibPhase 2Metastatic Breast Cancer With a Isolated Brain ProgressionOncologyApr 2025
NCT02625441trastuzumabPhase 3Breast CancerOncologyJun 2025
NCT03756896CarfilzomibPhase 2Plasma Cell MyelomaOncologyJun 2025
NCT06597916Respiratory Syncytial Virus Pre-Fusion Glycoprotein FPhase 2RSV InfectionInfectious diseaseAug 2025
NCT02778685PalbociclibPhase 2Metastatic Breast CarcinomaOncologyOct 2025
NCT06895733PalbociclibPhase 1Solid Tumor, AdultOncologyDec 2025
NCT06193525TalazoparibPhase 2Advanced Breast CancerOncologyDec 2025
NCT05190094PalbociclibPhase 2Hormonal Receptors Positive, HER2 Negative, Advanced Breast CancerOncologyDec 2025
NCT06973720Berobenatide (PF-08653944, MET097)Phase 2ObesityMetabolic and endocrineDec 2025
NCT06158412CarfilzomibPhase 2Multiple Myeloma in RelapseOncologyDec 2025
NCT05740943Lorlatinib (PF-06463922)Phase 2Stage III NSCLCOncologyDec 2025
NCT06597396AbrocitinibPhase 2Post-COVID ConditionInfectious diseaseMar 2026
NCT07406217Nirmatrelvir (PF-07321332)Phase 2COVID-19Infectious diseaseApr 2026
NCT07406217RemdesivirPhase 2COVID-19Infectious diseaseApr 2026
NCT03104842CarfilzomibPhase 2Multiple MyelomaOncologyMay 2026
NCT03500445CarfilzomibPhase 2MyelomaOncologyJun 2026
NCT06364956PalbociclibPhase 1Bladder CancerOncologyJun 2026
NCT03610438Inotuzumab ozogamicinPhase 2Acute Lymphoid LeukemiaOncologyJul 2026
NCT05261139Nirmatrelvir (PF-07321332)Phase 3COVID-19Infectious diseaseJul 2026
NCT05940961Inotuzumab ozogamicinPhase 2ALLOncologyAug 2026
NCT06965465PF-07999415Phase 1HealthyOtherAug 2026
NCT07153159EtrasimodPhase 1Healthy ParticipantOtherSep 2026
NCT05070845PF-06835375Phase 2Primary Immune ThrombocytopeniaHematologySep 2026
NCT06924320Berobenatide (PF-08653944, MET097)Phase 1Obesity and Obesity-related Medical ConditionsMetabolic and endocrineSep 2026
NCT06924320CMP 001Phase 1Obesity and Obesity-related Medical ConditionsMetabolic and endocrineSep 2026
NCT03609047PalbociclibPhase 2Breast Cancer Stage IIOncologySep 2026
NCT05573555CMP 001Phase 1Breast CancerOncologyOct 2026
NCT06447662PF-07934040Phase 1Carcinoma, Pancreatic DuctalOncologyOct 2026
NCT07073820PF-07868489Phase 2Pulmonary HypertensionCardiovascularOct 2026
NCT04657991EncorafenibPhase 3MelanomaOncologyOct 2026
NCT04657991BinimetinibPhase 3MelanomaOncologyOct 2026
NCT02877303Inotuzumab ozogamicinPhase 2B Acute Lymphoblastic LeukemiaOncologyNov 2026
NCT05995964tilrekimig (PF-07275315)Phase 2Atopic DermatitisImmunologyNov 2026
NCT05995964PF-07264660Phase 2Atopic DermatitisImmunologyNov 2026
NCT05323955tucatinibPhase 2Brain MetastasesOncologyNov 2026
NCT02912572TalazoparibPhase 2Metastatic Endometrial CancerOncologyNov 2026
NCT03104491Inotuzumab ozogamicinPhase 1Acute Lymphocytic LeukemiaOncologyNov 2026
NCT02605486PalbociclibPhase 1Metastatic Breast Cancer (MBC)OncologyNov 2026
NCT06249282CarfilzomibPhase 1Advanced Lung Non-Small Cell CarcinomaOncologyNov 2026
NCT05159245trastuzumabPhase 2Advanced CancerOncologyNov 2026
NCT06641466RimegepantPhase 3Menstrual MigraineNeurologyNov 2026
NCT06832865ElranatamabPhase 2Relapsed Refractory Multiple Myeloma (RRMM)OncologyDec 2026
NCT06015542ElranatamabPhase 2Multiple MyelomaOncologyDec 2026
NCT07108127trastuzumabPhase 2Rectal CancerOncologyDec 2026
NCT01959698CarfilzomibPhase 1CD20 PositiveOncologyDec 2026
NCT06992674RimegepantPhase 2Vestibular MigraineNeurologyDec 2026
NCT06387121Inotuzumab ozogamicinPhase 2Precursor Cell Lymphoblastic Leukemia-LymphomaOncologyDec 2026
NCT04165317SasanlimabPhase 3Non-muscle Invasive Bladder CancerOncologyDec 2026
NCT07029711RitlecitinibPhase 3Severe Alopecia AreataImmunologyDec 2026
NCT07500506CMP 001Phase 3Lyme DiseaseInfectious diseaseDec 2026

The 60 nearest readouts of 535 trials; the rest in the app.

From the company's SEC filings

Cash and short-term investments of $10.9bn on 2026-09-27; operating cash flow positive

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Complete response letters from FDA

Targets

CDK4 (3) ALK (3) ESR1 (3) BRAF (3) JAK1 (2) CDK6 (2) Tubulin (2) F3 (2) ITGB6 (2) ERBB2 (2) CD274 (2) F8 (2)

Companies with the same targets

Roche Novartis Eli Lilly AstraZeneca Jiangsu HengRui Medicine Chia Tai Tianqing Pharmaceutical Group Jiangsu Simcere Pharmaceutical Incyte Pharmacosmos Shandong Suncadia Medicine

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.